Method for manufacturing an artificial tumour-specific T cell receptor, comprising the steps of: - providing a tumour-specific T cell preparation by the steps of: a. selecting tumour-specific T cell clones by: - providing a tumour sample obtained from a patient; - isolating a nucleic acid preparation from said tumour sample in a nucleic acid isolation step; - obtaining a plurality of T cell receptor nucleic acid sequences from said nucleic acid preparation or a plurality of T cell receptor amino acid sequences encoded by said plurality of T cell receptor nucleic acid sequences; - selecting a tumour-specific T cell receptor nucleic acid sequence from said plurality of T cell receptor nucleic acid sequences or a tumour-specific T cell receptor amino acid sequence from said plurality of T cell receptor amino acid sequences in a sequence selection step; b. sorting tumour-specific T cell clones by: - providing a lymphocyte preparation obtained from said patient; - isolating cells that comprise said selected tumour-specific T cell receptor nucleic acid sequence or said selected tumour-specific T cell receptor amino acid sequence from said lymphocyte preparation in an isolation step; - isolating an individual tumour-specific T cell from said tumour-specific T cell preparation; - determining the CDR3 regions of both subunits of said T cell receptor of said isolated individual tumour-specific T cell; and - preparing an artificial T cell receptor comprising said determined CDR3 regions of both subunits. - providing a tumour-specific T cell preparation by the steps of: a. selecting tumour-specific T cell clones by: - providing a tumour sample obtained from a patient; - isolating a nucleic acid preparation from said tumour sample in a nucleic acid isolation step; - obtaining a plurality of T cell receptor nucleic acid sequences from said nucleic acid preparation or a plurality of T cell receptor amino acid sequences encoded by said plurality of T cell receptor nucleic acid sequences; - selecting a tumour-specific T cell receptor nucleic acid sequence from said plurality of T cell receptor nucleic acid sequences or a tumour-specific T cell receptor amino acid sequence from said plurality of T cell receptor amino acid sequences in a sequence selection step; b. sorting tumour-specific T cell clones by: - providing a lymphocyte preparation obtained from said patient; - isolating cells that comprise said selected tumour-specific T cell receptor nucleic acid sequence or said selected tumour-specific T cell receptor amino acid sequence from said lymphocyte preparation in an isolation step; a. selecting tumour-specific T cell clones by: - providing a tumour sample obtained from a patient; - isolating a nucleic acid preparation from said tumour sample in a nucleic acid isolation step; - obtaining a plurality of T cell receptor nucleic acid sequences from said nucleic acid preparation or a plurality of T cell receptor amino acid sequences encoded by said plurality of T cell receptor nucleic acid sequences; - selecting a tumour-specific T cell receptor nucleic acid sequence from said plurality of T cell receptor nucleic acid sequences or a tumour-specific T cell receptor amino acid sequence from said plurality of T cell receptor amino acid sequences in a sequence selection step; - providing a tumour sample obtained from a patient; - isolating a nucleic acid preparation from said tumour sample in a nucleic acid isolation step; - obtaining a plurality of T cell receptor nucleic acid sequences from said nucleic acid preparation or a plurality of T cell receptor amino acid sequences encoded by said plurality of T cell receptor nucleic acid sequences; - selecting a tumour-specific T cell receptor nucleic acid sequence from said plurality of T cell receptor nucleic acid sequences or a tumour-specific T cell receptor amino acid sequence from said plurality of T cell receptor amino acid sequences in a sequence selection step; b. sorting tumour-specific T cell clones by: - providing a lymphocyte preparation obtained from said patient; - isolating cells that comprise said selected tumour-specific T cell receptor nucleic acid sequence or said selected tumour-specific T cell receptor amino acid sequence from said lymphocyte preparation in an isolation step; - providing a lymphocyte preparation obtained from said patient; - isolating cells that comprise said selected tumour-specific T cell receptor nucleic acid sequence or said selected tumour-specific T cell receptor amino acid sequence from said lymphocyte preparation in an isolation step; - isolating an individual tumour-specific T cell from said tumour-specific T cell preparation; - determining the CDR3 regions of both subunits of said T cell receptor of said isolated individual tumour-specific T cell; and - preparing an artificial T cell receptor comprising said determined CDR3 regions of both subunits.